Trial Profile
Cardiovascular disease risk associated with tocilizumab compared with tumour necrosis inhibitor (TNFi) therapies and other biologics in patients with rheumatoid arthritis: A retrospective cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Abatacept; Adalimumab; Etanercept; Infliximab; Rituximab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 15 Jul 2018 New trial record